Thank you! There have been a few smaller biotechs that have had regulatory success with their Covid products, but it seems like all of them have Big Pharma partners and are splitting the revenue. So Big Pharma treats us equally.
I would like to resume my full position in CYDY if share price falls to below $1.00. Even after accounting for Humanigen's reverse split, CYDY has twice as many shares Outstanding, and I think the better value is with HGEN.
I talk about "double-oughtober" because I think it is possible that we could get Market Authorization from the UK this month, and a reversal of the FDA's decline determination. Probably most everybody thinks that's too early, and perhaps it is. But I actually think it is far too late. We should have become revenue-producing and saving lives by now.
Market Data 
Markets 
AI
